Table 5.
Analysis of correlation of Yes‐associated protein expression in hepatocellular carcinoma with clinicopathological features using a fixed effects model
| Clinicopathological features feature | OR (95% CI) | P‐value (Z test) | I 2 (%) | Heterogeneity | Egger's test P‐value | Begg's test P‐value |
|---|---|---|---|---|---|---|
| Sexa | 0.93 (0.61, 1.42) | .74 | 18 | .29 | .371 | .453 |
| Tumour numberb | 1.17 (0.82, 1.67) | .38 | 55 | .06 | .524 | .624 |
| Cellular differentiationc | 2.38 (1.61, 3.51) | <.00001 | 13 | .33 | .05 | .039 |
| Serum AFPd | 4.09 (2.59, 6.45) | <.00001 | 55 | .08 | .230 | .174 |
| Venous infiltratione | 2.21 (1.64, 2.97) | <.00001 | 42 | .11 | .791 | .621 |
| Hepatitisf | 0.9 (0.55, 1.47) | .66 | 5 | .38 | .933 | .573 |
| AJCC tumour stageg | 0.77 (0.48, 1.23) | .27 | 66 | .05 | .612 | .602 |
| TNM tumour stageh | 0.44 (0.28, 0.69) | .0003 | 48 | .12 | .586 | .497 |
| Tumour sizei | 2.52 (1.75, 3.62) | <.00001 | 40 | .17 | .899 | 1.000 |
a
Male/female.
b
Multiple/single.
c
Low differentiation/middle or high differentiation.
d
>400 ng/mL/<400 μg/mL.
e
Y/N.
f
Y/N.
g
I/II + III.
h
I + II/III + IV.
i
>5 cm/<5 cm.